These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

812 related items for PubMed ID: 22050138

  • 1. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [Abstract] [Full Text] [Related]

  • 2. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
    Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.
    Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
    [Abstract] [Full Text] [Related]

  • 3. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH, de Vries EG, Vedelaar SR, Timmer-Bosscha H, Schröder CP, Brouwers AH, Lub-de Hooge MN.
    Mol Pharm; 2012 Nov 05; 9(11):2995-3002. PubMed ID: 23003202
    [Abstract] [Full Text] [Related]

  • 4. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
    Leow CC, Chesebrough J, Coffman KT, Fazenbaker CA, Gooya J, Weng D, Coats S, Jackson D, Jallal B, Chang Y.
    Mol Cancer Ther; 2009 Aug 05; 8(8):2131-41. PubMed ID: 19671750
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W, Wu QD, Zhang M, Kong YL, Cao PR, Zheng W, Xu JH, Ye M.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):862-71. PubMed ID: 25449780
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Assessing the impact of HER2 status on the antitumor activity of an HSP90 inhibitor in human tumor xenograft mice using pharmacokinetic-pharmacodynamic modeling.
    Saitoh R, Nagayasu M, Shibahara N, Ono N, Suda A, Kato M, Ishigai M.
    Drug Metab Pharmacokinet; 2014 Jan 28; 29(2):185-91. PubMed ID: 24126359
    [Abstract] [Full Text] [Related]

  • 11. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.
    Breast Cancer Res Treat; 2011 Nov 28; 130(1):29-40. PubMed ID: 21153051
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr 28; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 13. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
    Fujimoto-Ouchi K, Sekiguchi F, Yamamoto K, Shirane M, Yamashita Y, Mori K.
    Cancer Chemother Pharmacol; 2010 Jul 28; 66(2):269-76. PubMed ID: 19904537
    [Abstract] [Full Text] [Related]

  • 14. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G.
    Immunol Lett; 2006 Apr 15; 104(1-2):146-55. PubMed ID: 16384610
    [Abstract] [Full Text] [Related]

  • 15. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C.
    Clin Cancer Res; 2011 Aug 01; 17(15):5132-9. PubMed ID: 21558407
    [Abstract] [Full Text] [Related]

  • 16. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK.
    Proc Natl Acad Sci U S A; 2006 Nov 14; 103(46):17408-13. PubMed ID: 17090671
    [Abstract] [Full Text] [Related]

  • 17. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
    Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA.
    J Clin Oncol; 2007 Dec 01; 25(34):5410-7. PubMed ID: 18048823
    [Abstract] [Full Text] [Related]

  • 18. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C, Nitzsche B, Lim AR, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H, Höpfner M.
    Int J Oncol; 2012 May 01; 40(5):1659-67. PubMed ID: 22246317
    [Abstract] [Full Text] [Related]

  • 19. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
    Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S.
    Int J Oncol; 2005 Sep 01; 27(3):681-5. PubMed ID: 16077916
    [Abstract] [Full Text] [Related]

  • 20. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS, Raja SM, Kim JO, Mohapatra B, Soni KS, Luan H, Williams SH, Bielecki TA, Feng D, Storck M, Band V, Cohen SM, Band H, Bronich TK.
    J Control Release; 2015 Jun 28; 208():59-66. PubMed ID: 25660204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.